CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended		110 Months Ended	9 Months Ended	110 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012 Lipimetix [Member]	Sep. 30, 2013 Lipimetix Azerx Cbi [Member]
OPERATING ACTIVITIES
Net loss	$ (3,399)	$ (2,830)	$ (153,845)
Non cash items:
Deferred tax expense	0	0	770
Depreciation and amortization, net of gain on sale	132	(14)	4,103
Non-cash stock compensation	29	104	4,960
Gain on sale of bone device business	0	0	(2,298)
In-process research and development	0	0	34,311
Change in other operating items:
Interest, income taxes and other current assets	300	428	1,625
Accounts payable	(33)	132	(771)
Accrued liabilities	(55)	(37)	(3,010)
Cash flows used in operating activities	(3,026)	(2,217)	(114,155)
INVESTING ACTIVITIES
Expenditures for furniture and equipment, net	0	0	(1,044)
Proceeds from sale of assets	4	172	7,176
Cash paid for assets of AzERx/CBI	0	0	(4,058)	378	4,436
Cash paid for patent rights	0	(378)	(1,028)
Purchases of investments	0	0	(282,538)
Maturities of investments	0	0	340,476
Cash flows provided by (used in) investing activities	4	(206)	58,984
FINANCING ACTIVITIES
Net proceeds from stock option exercises	0	0	4,612
Net proceeds from sale of stock	0	0	3,376
Common stock purchases	0	0	(1,041)
Cash flows provided by financing activities	0	0	6,947
NET DECREASE IN CASH AND CASH EQUIVALENTS	(3,022)	(2,423)	(48,224)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	10,205	13,778	55,407
CASH AND CASH EQUIVALENTS, END OF PERIOD	7,183	11,355	7,183
Supplemental Disclosure of Non-Cash Investing Activities -
Current assets acquired				0	29
Patent license rights				1,045	3,187
Liabilities acquired, and accrued acquisition costs				0	(457)
Original investment reversal				0	(750)
In-process research and development acquired				0	34,311
Noncontrolling interests				(667)	(667)
Common stock issued for acquisition				0	(31,217)
Cash paid	$ 0	$ 0	$ (4,058)	$ 378	$ 4,436